{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Vein+Thrombosis&page=23",
    "query": {
      "condition": "Vein Thrombosis",
      "page": 23
    },
    "page_size": 10
  },
  "pagination": {
    "page": 23,
    "page_size": 10,
    "total_count": 553,
    "total_pages": 56,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Vein+Thrombosis&page=24&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Vein+Thrombosis&page=22&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-15T13:46:22.356Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01006733",
      "title": "Genetics Informatics Trial (GIFT) of Warfarin to Prevent DVT",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Thromboembolism"
      ],
      "interventions": [
        {
          "name": "Pharmacogenetic",
          "type": "GENETIC"
        },
        {
          "name": "Target INR 1.8",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "GENETIC",
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "65 Years and older"
      },
      "enrollment_count": 1598,
      "start_date": "2011-03",
      "completion_date": "2016-11",
      "has_results": false,
      "last_update_posted_date": "2016-12-29",
      "last_synced_at": "2026-10-15T13:46:22.356Z",
      "location_count": 6,
      "location_summary": "Chicago, Illinois • St Louis, Missouri • New York, New York + 2 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01006733"
    },
    {
      "nct_id": "NCT03203447",
      "title": "Suprachoroidal Injection of Triamcinolone Acetonide With IVT Anti-VEGF in Subjects With Macular Edema Following RVO",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Macular Edema",
        "Retinal Vein Occlusion"
      ],
      "interventions": [
        {
          "name": "suprachoroidal CLS-TA",
          "type": "DRUG"
        },
        {
          "name": "suprachoroidal sham",
          "type": "DRUG"
        },
        {
          "name": "Lucentis or Avastin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Clearside Biomedical, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 325,
      "start_date": "2018-03-05",
      "completion_date": "2018-12-18",
      "has_results": true,
      "last_update_posted_date": "2021-04-23",
      "last_synced_at": "2026-10-15T13:46:22.356Z",
      "location_count": 72,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 61 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Arcadia",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03203447"
    },
    {
      "nct_id": "NCT00694382",
      "title": "Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Cancer Patients Undergoing Chemotherapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Venous Thromboembolism",
        "Cancer"
      ],
      "interventions": [
        {
          "name": "Semuloparin sodium",
          "type": "DRUG"
        },
        {
          "name": "Placebo (for semuloparin)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3212,
      "start_date": "2008-06",
      "completion_date": "2010-11",
      "has_results": false,
      "last_update_posted_date": "2013-01-23",
      "last_synced_at": "2026-10-15T13:46:22.356Z",
      "location_count": 48,
      "location_summary": "Birmingham, Alabama • Casa Grande, Arizona • Tucson, Arizona + 43 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Casa Grande",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00694382"
    },
    {
      "nct_id": "NCT03080883",
      "title": "Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cerebral Vein Thrombosis",
        "Deep Vein Thrombosis",
        "Hematopoietic and Lymphoid Cell Neoplasm",
        "Malignant Solid Neoplasm",
        "Metastatic Malignant Solid Neoplasm",
        "Pulmonary Embolism",
        "Splanchnic Vein Thrombosis"
      ],
      "interventions": [
        {
          "name": "Apixaban",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Academic and Community Cancer Research United",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 370,
      "start_date": "2017-07-14",
      "completion_date": "2025-05-09",
      "has_results": true,
      "last_update_posted_date": "2025-05-18",
      "last_synced_at": "2026-10-15T13:46:22.356Z",
      "location_count": 32,
      "location_summary": "Scottsdale, Arizona • Washington D.C., District of Columbia • Jacksonville, Florida + 27 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Weston",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03080883"
    },
    {
      "nct_id": "NCT02889562",
      "title": "Apixaban Versus Warfarin for the Management of Post-operative Atrial Fibrillation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Coronary Artery Bypass Grafting",
        "Postoperative Atrial Fibrilation",
        "Stroke",
        "Systemic Embolism",
        "Deep Venous Thrombosis"
      ],
      "interventions": [
        {
          "name": "Apixaban",
          "type": "DRUG"
        },
        {
          "name": "Warfarin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanford Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 56,
      "start_date": "2016-09",
      "completion_date": "2019-05-11",
      "has_results": true,
      "last_update_posted_date": "2021-01-22",
      "last_synced_at": "2026-10-15T13:46:22.356Z",
      "location_count": 1,
      "location_summary": "Fargo, North Dakota",
      "locations": [
        {
          "city": "Fargo",
          "state": "North Dakota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02889562"
    },
    {
      "nct_id": "NCT07005024",
      "title": "DOAC - Dosing Options in AntiCoagulation Prophylaxis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cancer",
        "VTE (Venous Thromboembolism)"
      ],
      "interventions": [
        {
          "name": "Apixaban 2.5 mg twice daily",
          "type": "DRUG"
        },
        {
          "name": "Apixaban 5 mg once daily",
          "type": "DRUG"
        },
        {
          "name": "No anticoagulation",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Vermont",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 996,
      "start_date": "2025-10-17",
      "completion_date": "2035-08",
      "has_results": false,
      "last_update_posted_date": "2026-02-05",
      "last_synced_at": "2026-10-15T13:46:22.356Z",
      "location_count": 1,
      "location_summary": "Burlington, Vermont",
      "locations": [
        {
          "city": "Burlington",
          "state": "Vermont"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07005024"
    },
    {
      "nct_id": "NCT00927862",
      "title": "Applying Pharmacogenetic Algorithms to Individualize Dosing of Warfarin",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Thromboembolism"
      ],
      "interventions": [
        {
          "name": "IWPC adapted genotype-guided dosing algorithm for warfarin",
          "type": "GENETIC"
        },
        {
          "name": "Modified IWPC genetic-guided warfarin dosing algorithm",
          "type": "GENETIC"
        },
        {
          "name": "Standard of care treatment",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "GENETIC",
        "OTHER"
      ],
      "sponsor": "Intermountain Health Care, Inc.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2415,
      "start_date": "2008-08",
      "completion_date": "2011-06",
      "has_results": true,
      "last_update_posted_date": "2012-09-25",
      "last_synced_at": "2026-10-15T13:46:22.356Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00927862"
    },
    {
      "nct_id": "NCT00371683",
      "title": "Study of Apixaban for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Deep Vein Thrombosis",
        "Pulmonary Embolism"
      ],
      "interventions": [
        {
          "name": "Enoxaparin + Placebo",
          "type": "DRUG"
        },
        {
          "name": "Apixaban + Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3608,
      "start_date": "2006-11",
      "completion_date": "2008-05",
      "has_results": true,
      "last_update_posted_date": "2015-12-30",
      "last_synced_at": "2026-10-15T13:46:22.356Z",
      "location_count": 25,
      "location_summary": "Birmingham, Alabama • Tuscaloosa, Alabama • Little Rock, Arkansas + 17 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tuscaloosa",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00371683"
    },
    {
      "nct_id": "NCT00407355",
      "title": "Ranibizumab (Lucentis) for Macular Edema Secondary to Vein Occlusions",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Macular Edema",
        "Retinal Vein Occlusion"
      ],
      "interventions": [
        {
          "name": "Intravitreal injection of ranibizumab .3 dose",
          "type": "DRUG"
        },
        {
          "name": "Intravitreal injection of Ranibizumab .5 dose",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Peter A Campochiaro, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2006-01",
      "completion_date": "2013-02",
      "has_results": true,
      "last_update_posted_date": "2013-12-04",
      "last_synced_at": "2026-10-15T13:46:22.356Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00407355"
    },
    {
      "nct_id": "NCT07699796",
      "title": "Apixaban vs Rivaroxaban vs No Anticoagulant to Prevent EHIT After Great Saphenous Vein Laser Ablation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Venous Thrombosis Deep (Limbs)",
        "Venous Insufficiency (Chronic)(Peripheral)",
        "Varicose Veins Leg",
        "Venous Thrombosis"
      ],
      "interventions": [
        {
          "name": "Apixaban",
          "type": "DRUG"
        },
        {
          "name": "Rivaroxaban",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Heart, Artery, and Vein Center of Fresno",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 564,
      "start_date": "2018-03-06",
      "completion_date": "2021-06-15",
      "has_results": false,
      "last_update_posted_date": "2026-07-16",
      "last_synced_at": "2026-10-15T13:46:22.356Z",
      "location_count": 1,
      "location_summary": "Fresno, California",
      "locations": [
        {
          "city": "Fresno",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07699796"
    }
  ]
}